Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Pär Stattin"'
Autor:
Johan Syrjä, Mats Lambe, David Robinson, Irma Fredriksson, Pär Stattin, Rolf Gedeborg, Malin Sund, Hans Garmo, Anna Plym, Lars Holmberg
Publikováno v:
Epidemiology. 32:607-615
Background The ability to account for comorbidity when estimating survival in a population diagnosed with cancer could be improved by using a drug comorbidity index based on filled drug prescriptions. Methods We created a drug comorbidity index from
Autor:
Suzanne Kilany, Ingela Franck Lissbrant, Karin Fagerlund, Johanna Svensson, Pär Stattin, Oskar Gauffin, Marie Hjälm-Eriksson
Publikováno v:
Scandinavian Journal of Urology. 55:1-8
To investigate time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer in Sweden, and the associated health economic impact.Registry study (NCT03619980) of the Prostate Cancer data Base Sweden with
Publikováno v:
Journal of Urology. 204:714-719
5α-Reductase inhibitors reduced the risk of prostate cancer in 25% in 2 randomized trials but increased the risk of Gleason 8-10 at biopsy. One explanation is that 5α-reductase inhibitors induce morphological changes in prostate cancer cells simila
Autor:
Andri Wilberg Orrason, Marcus Westerberg, Peter Albertsen, Johan Styrke, David Robinson, Hans Garmo, Pär Stattin
The main aim of the study was to determine the impact of diagnostic activity and life expectancy on the lifetime risk of a prostate cancer diagnosis. We used a state transition simulation model based on Swedish population-based data to simulate life
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb206a39f916b835813aef652ecab8f6
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-471669
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-471669
Autor:
Jan Adolfsson, Pär Stattin, Beth Russell, Kerri Beckmann, Christel Häggström, Hans Garmo, Mieke Van Hemelrijck, Lars Holmberg, Debra H. Josephs
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
Beckmann, K, Russell, B, Josephs, D, Garmo, H, Häggström, C, Holmberg, L, Stattin, P, Van Hemelrijck, M & Adolfsson, J 2019, ' Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer : a population-based case-control study ', BMC Cancer .
BMC Cancer
Beckmann, K, Russell, B, Josephs, D, Garmo, H, Häggström, C, Holmberg, L, Stattin, P, Van Hemelrijck, M & Adolfsson, J 2019, ' Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer : a population-based case-control study ', BMC Cancer .
Background Whether chronic inflammation increases prostate cancer risk remains unclear. This study investigated whether chronic inflammatory diseases (CID) or anti-inflammatory medication use (AIM) were associated with prostate cancer risk. Methods F
Publikováno v:
Scandinavian Journal of Urology. 53:134-138
Objectives: To estimate the incidence of men seeking specialized care and receiving treatment for hydro or spermatocele complaints. Also, to determine the risk of complications of treatment.Materia...
Publikováno v:
American Journal of Epidemiology
Net survival, estimated in a relative survival (RS) or cause-specific survival (CSS) framework, is a key measure of the effectiveness of cancer management. We compared RS and CSS in men with prostate cancer (PCa) according to age and risk category, u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a07f1ed0c24a0e2aab9a6bb6ca1c45e3
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-460914
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-460914
Autor:
E. Lin, Danielle Crawley, Mieke Van Hemelrijck, Jan Adolfsson, Pär Stattin, Hans Garmo, Björn Zethelius
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Background Gonadotropin Releasing Hormones agonists (GnRH), which are first line treatment for metastatic prostate cancer (PCa), increase risk of type 2 diabetes mellitus (T2DM). This study aims to quantify the association of use of GnRH with diabete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc586b9635c30fdf5848af296b0878d1
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-460220
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-460220
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0255239 (2021)
PLoS ONE
PLoS ONE
Background The Charlson Comorbidity Index is a poor predictor of mortality in men with castration resistant prostate cancer (CRPC). To improve this prediction, we created a comorbidity index based on filled prescriptions intended to be used in regist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b32374fdb531bc2e7d9240c1750c591
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-453480
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-453480
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 10, p e0255966 (2021)
PLoS ONE, Vol 16, Iss 10, p e0255966 (2021)
Background Men have a higher risk of death from COVID-19 than women and androgens facilitate entrance of the SARS-CoV-2 virus into respiratory epithelial cells. Thus, androgen deprivation therapy may reduce infection rates and improve outcomes for CO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b7a7a4318ba0e5fcbce3829a252b83
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-188489
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-188489